Active, not recruitingPhase 3NCT04640142
Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases
Studying Primary immunodeficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Octapharma
- Intervention
- Newnorm(biological)
- Enrollment
- 50 enrolled
- Eligibility
- 2-75 years · All sexes
- Timeline
- 2021 – 2026
Study locations (22)
- Octapharma Research Site, Irvine, California, United States
- Octapharma Research Site, Centennial, Colorado, United States
- Octapharma Research Site, Hollywood, Florida, United States
- Octapharma Research Site, Port Saint Lucie, Florida, United States
- Octapharma Research Site, St. Petersburg, Florida, United States
- Octapharma Research Site, Chicago, Illinois, United States
- Octapharma Research Site, Overland Park, Kansas, United States
- Octapharma Research Site, Louisville, Kentucky, United States
- Octapharma Research Site, White Marsh, Maryland, United States
- Octapharma Research Site, Kansas City, Missouri, United States
- Octapharma Research Site, Omaha, Nebraska, United States
- Octapharma Research Site, Leipzig, Germany
- Octapharma Research Site, Munich, Germany
- Octapharma Research Site, Budapest, Hungary
- Octapharma Research Site, Debrecen, Hungary
- +7 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04640142 on ClinicalTrials.govOther trials for Primary immunodeficiency
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE4NCT07076446An Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, and Tolerability of Subcutaneous IgPro20 in Immunoglobulin (IG) Treatment-naïve Participants With Primary Immunodeficiency (PID)CSL Behring
- RECRUITINGPHASE1, PHASE2NCT06839456Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCTChildren's Hospital of Philadelphia
- RECRUITINGNCT06565078A Database Survey to Evaluate the Safety of Immune Globulin Subcutaneous (Human), 20% Solution in Participants With Primary ImmunodeficiencyTakeda
- RECRUITINGNANCT07261891Ex Vivo Evaluation of JAK-inhibitor and Gene Therapeutical Approach in JAK-STAT Related Disordersprof. dr. Rik Schrijvers
- ENROLLING BY INVITATIONNCT06144229Real-world Effectiveness of HPV Vaccine in Women Living With HIV and Its Impact on Cervical Cancer Screening AccuraciesUniversity of California, Los Angeles
- ACTIVE NOT RECRUITINGPHASE2NCT06549114Leniolisib for Immune Dysregulation in PIDsPharming Technologies B.V.
- RECRUITINGNANCT06659588Study of Populations at Risk of Developing Chronic Hepatitis Linked to Chronic Enteric Virus Infection in Patients With Primary Immunodeficiency and Secondary Humoral DeficiencyAssistance Publique - Hôpitaux de Paris
- RECRUITINGNANCT07004803Virtual Reality on Pain and Fear Levels of Children With Primary ImmunodeficiencyDr. Hatice Dönmez